Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2022 Results of pooled analysis (n=439) assessing the safety of avacopan from two Phase 2 (CLEAR and CLASSIC) and one Phase 3 studies (ADVOCATE) in patients with ANCA-Associated Vasculitis, presented at the ACR Convergence 2022.
11 Apr 2018 Accoridng to ChemoCentryx media release, safety, renal parameters and quality of life outcomes from this study are being presented during the 2018 Spring Clinical Meetings of the National Kidney Foundation (NKF).
07 Nov 2016 Accoridng to ChemoCentryx media release, positive results will be presented at the American Society of Nephrology (ASN) Kidney Week 2016

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com